Differences between Spaniards and Ecuadorians in CYP2A6 allele frequencies: Comparison with other populations

Fundamental and Clinical Pharmacology

Volumn 25, Issue 5, 2011, Pages 627-632

  Soriano, Antonia ^a   Vicente, Jorge ^a   Carcas, Cristina ^a   Gonzalez Andrade, Fabricio ^b   Arenaz, Izaskún ^a   Martinez Jarreta, Begoña ^a   Fanlo, Ana ^a   Mayayo, Esteban ^a   Sinués, Blanca ^a  

^a UNIVERSITY OF ZARAGOZA   (Spain)

^b UNIVERSIDAD CENTRAL DEL ECUADOR   (Ecuador)

Author keywords

CYP2A6 polymorphism; Ecuadorians; Ethnic differences; Pharmacogenetic markers; Spaniards

Indexed keywords

CYTOCHROME P450 2A6;

ADULT; AFRICAN AMERICAN; ARTICLE; ASIAN; CAUCASIAN; ECUADORIAN; ENZYME ACTIVITY; ETHNIC AND RACIAL GROUPS; FEMALE; GENE DELETION; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; POINT MUTATION; PRIORITY JOURNAL; RACE DIFFERENCE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SPANIARD;

ADOLESCENT; ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; ALLELES; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; DNA; ECUADOR; ETHNIC GROUPS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NICOTINE; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; SMOKING; SPAIN; TOBACCO, SMOKELESS; YOUNG ADULT;

EID: 80052902536     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2010.00889.x     Document Type: Article

References (37)

1. Nakajima M., Yamamoto T., Nunoya K. et al. Role of human cytochrome P4502A6 in C-oxidation of nicotine. Drug Metab. Dispos. (1996) 24 1212-1217.
2. Nakajima M., Kuroiwa Y., Yokoi T. Interindividual differences in nicotine metabolism and genetic polymorphisms of human CYP2A6. Drug Metab. Rev. (2002) 34 865-877.
3. Yun C.H., Shimada T., Guengerich F.P. Purification and characterization of human liver microsomal cytochrome P-450 2A6. Mol. Pharmacol. (1991) 40 679-685.
4. Pelkonen O., Rautio A., Raunio H., Pasanen M. CYP2A6: a human coumarin 7-hydroxylase. Toxicology (2000) 144 139-147.
5. Rao Y., Hoffmann E., Zia M. et al. Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking. Mol. Pharmacol. (2000) 58 747-755.
6. Oscarson M., McLellan R.A., Gullstén H. et al. Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism. FEBS Lett. (1999) 460 321-327.
7. Oscarson M., McLellan R.A., Asp V. et al. Characterization of a novel CYP2A7/CYP2A6 hybrid allele (CYP2A6*12) that causes reduced CYP2A6 activity. Hum. Mutat. (2002) 20 275-283.
8. Oscarson M., McLellan R.A., Gullstén H. et al. Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population. FEBS Lett. (1999) 448 105-110.
9. Nunoya K.I., Yokoi T., Kimura K. et al. A new CYP2A6 gene deletion responsible for the in vivo polymorphic metabolism of (+)-cis-3, 5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride in humans. J. Pharmacol. Exp. Ther. (1999) 289 437-442.
10. Pitarque M., von Richter O., Oke B., Berkkan H., Oscarson M., Ingelman-Sundberg M. Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity. Biochem. Biophys. Res. Commun. (2001) 284 455-460.
11. Yoshida R., Nakajima M., Nishimura K., Tokudome S., Kwon J.T., Yokoi T. Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro. Clin. Pharmacol. Ther. (2003) 74 69-76.
12. Kitagawa K., Kunugita N., Katoh T., Yang M., Kawamoto T. The significance of the homozygous CYP2A6 deletion on nicotine metabolism: a new genotyping method of CYP2A6 using a single PCR-RFLP. Biochem. Biophys. Res. Commun. (1999) 262 146-151.
13. Nakajima M., Yamagishi S., Yamamoto H., Yamamoto T., Kuroiwa Y., Yokoi T. Deficient cotinine formation from nicotine is attributed to the whole deletion of the CYP2A6 gene in humans. Clin. Pharmacol. Ther. (2000) 67 57-69.
14. Kwon J.T., Nakajima M., Chai S. et al. Nicotine metabolism and CYP2A6 allele frequencies in Koreans. Pharmacogenetics (2001) 11 317-323.
15. Gambier N., Batt A.M., Marie B., Pfister M., Siest G., Visvikis-Siest S. Association of CYP2A6*1B genetic variant with the amount of smoking in French adults from the Stanislas cohort. Pharmacogenomics J. (2005) 5 271-275.
16. Ariyoshi N., Miyamoto M., Umetsu Y. et al. Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers. Cancer Epidemiol. Biomarkers Prev. (2002) 11 890-894.
17. Fujieda M., Yamazaki H., Saito T. et al. Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers. Carcinogenesis (2004) 25 2451-2458.
18. Miyamoto M., Umetsu Y., Dosaka-Akita H. et al. CYP2A6 gene deletion reduces susceptibility to lung cancer. Biochem. Biophys. Res. Commun. (1999) 261 658-660.
19. Ruwali M., Pant M.C., Shah P.P., Mishra B.N., Parmar D. Polymorphism in cytochrome P450 2A6 and glutathione S-transferase P1 modifies head and neck cancer risk and treatment outcome. Mutat. Res. (2009) 669 36-41.
20. Canova C., Hashibe M., Simonato L. et al. Genetic associations of 115 polymorphisms with cancers of the upper aerodigestive tract across 10 European countries: the ARCAGE project. Cancer Res. (2009) 69 2956-2965.
21. Tan W., Chen G.F., Xing D.Y., Song C.Y., Kadlubar F.F., Lin D.X. Frequency of CYP2A6 gene deletion and its relation to risk of lung and esophageal cancer in the Chinese population. Int. J. Cancer (2001) 95 96-101.
22. Song D.K., Xing D.L., Zhang L.R., Li Z.X., Liu J., Qiao B.P. Association of NAT2, GSTM1, GSTT1, CYP2A6, and CYP2A13 gene polymorphisms with susceptibility and clinicopathologic characteristics of bladder cancer in Central China. Cancer Detect. Prev. (2009) 32 416-423.
23. Agúndez J.A., Gallardo L., Ledesma M.C. et al. Functionally active duplications of the CYP2D6 gene are more prevalent among larynx and lung cancer patients. Oncology (2001) 61 59-63.
24. Pianezza M.L., Sellers E.M., Tyndale R.F. Nicotine metabolism defect reduces smoking. Nature (1998) 393 750.
25. Schoedel K.A., Hoffmann E.B., Rao Y., Sellers E.M., Tyndale R.F. Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. Pharmacogenetics (2004) 14 615-626.
26. Bernal M.L., Sinues B., Johansson I. et al. Ten percent of North Spanish individuals carry duplicated or triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine. Pharmacogenetics (1999) 9 657-660.
27. Agúndez J.A., Martínez C., Ledesma M.C., Ladona M.G., Ladero J.M., Benítez J. Genetic basis for differences in debrisoquin polymorphism between a Spanish and other white populations. Clin. Pharmacol. Ther. (1994) 55 412-417.
28. Oscarson M., Gullstén H., Rautio A. et al. Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C-oxidase. FEBS Lett. (1998) 438 201-205.
29. Gullstén H., Agúndez J.A., Benítez J. et al. CYP2A6 gene polymorphism and risk of liver cancer and cirrhosis. Pharmacogenetics. (1997) 7 247-250.
30. Nakajima M., Kwon J.T., Tanaka N. et al. Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans. Clin. Pharmacol. Ther. (2001) 69 72-78.
31. Yoshida R., Nakajima M., Nishimura K., Tokudome S., Kwon J.T., Yokoi T. Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro. Clin. Pharmacol. Ther. (2003) 74 69-76.
32. Yoshida R., Nakajima M., Watanabe Y., Kwon J.T., Yokoi T. Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism. Br. J. Clin. Pharmacol. (2002) 54 511-517.
33. Gyamfi M.A., Fujieda M., Kiyotani K., Yamazaki H., Kamataki T. High prevalence of cytochrome P450 2A6*1A alleles in a black African population of Ghana. Eur. J. Clin. Pharmacol. (2005) 60 855-857.
34. Bosch E., Calafell F., Comas D., Oefner P.J., Underhill P.A., Bertranpetit J. High-resolution analysis of human Y-chromosome variation shows a sharp discontinuity and limited gene flow between northwestern Africa and the Iberian Peninsula. Am. J. Hum. Genet. (2001) 68 1019-1029.
35. Daigo S., Takahashi Y., Fujieda M. et al. A novel mutant allele of the CYP2A6 gene (CYP2A6*11) found in a cancer patient who showed poor metabolic phenotype towards tegafur. Pharmacogenetics (2002) 12 299-306.
36. Chen G.F., Tang Y.M., Green B. et al. Low frequency of CYP2A6 gene polymorphism as revealed by a one-step polymerase chain reaction method. Pharmacogenetics (1999) 9 327-332.
37. Gaedigk A., Blum M., Gaedigk R., Eichelbaum M., Meyer U.A. Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. Am. J. Hum. Genet. (1991) 48 943-950.